Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 82 entries
View as:

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00741819 Org: User:
Start: 09/30/08 End: 12/31/10 Due: 12/31/11

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

Phase: N/A Priority: Normal
NCT ID: NCT00439946 Org: User:
Start: 02/28/07 End: 03/31/11 Due: 03/31/12

Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00494533 Org: User:
Start: 03/31/05 End: 10/31/05 Due: 10/31/06

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Phase: N/A Priority: Normal
NCT ID: NCT03045029 Org: User:
Start: 07/18/17 End: 12/31/25 Due: 12/31/26

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT03497689 Org: User:
Start: 01/31/19 End: 05/11/22 Due: 05/11/23

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00969722 Org: User:
Start: 08/31/09 End: - Due: -

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT01592045 Org: User:
Start: 08/31/12 End: 06/30/14 Due: 06/30/15

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Phase: N/A Priority: Normal
NCT ID: NCT00775463 Org: User:
Start: 05/31/09 End: 07/31/11 Due: 07/31/12

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

Phase: N/A Priority: Normal
NCT ID: NCT01165476 Org: User:
Start: 07/31/10 End: 08/31/10 Due: 08/31/11

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Phase: N/A Priority: Normal
NCT ID: NCT01477333 Org: User:
Start: 10/31/11 End: 11/30/13 Due: 11/30/14

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Phase: N/A Priority: Normal
NCT ID: NCT03016468 Org: User:
Start: 05/31/17 End: 09/30/18 Due: 09/30/19

Remodulin® to Oral Treprostinil Transition

Phase: N/A Priority: Normal
NCT ID: NCT01588405 Org: User:
Start: 04/30/12 End: 12/31/14 Due: 12/31/15

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Phase: N/A Priority: Normal
NCT ID: NCT02630316 Org: User:
Start: 02/03/17 End: 12/26/19 Due: 12/26/20

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02893995 Org: User:
Start: 02/28/17 End: 04/30/18 Due: 04/30/19

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

Phase: N/A Priority: Normal
NCT ID: NCT03857841 Org: User:
Start: 10/09/19 End: 05/20/21 Due: 05/20/22

Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00004497 Org: User:
Start: 10/31/98 End: 09/30/00 Due: 09/30/01

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT05203510 Org: User:
Start: 10/20/22 End: 04/30/28 Due: 04/30/29

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

Phase: N/A Priority: Normal
NCT ID: NCT03888365 Org: User:
Start: 04/01/19 End: 09/19/19 Due: 09/19/20

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03098030 Org: User:
Start: 06/01/17 End: 03/26/20 Due: 03/26/21

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00848939 Org: User:
Start: 12/31/08 End: 04/30/10 Due: 04/30/11

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

Phase: N/A Priority: Normal
NCT ID: NCT03037580 Org: User:
Start: 08/15/17 End: 12/03/19 Due: 12/03/20

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT01027949 Org: User:
Start: 01/16/07 End: 02/12/20 Due: 02/12/21

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Phase: N/A Priority: Normal
NCT ID: NCT01266265 Org: User:
Start: 12/31/10 End: 12/31/14 Due: 12/31/15

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Phase: N/A Priority: Normal
NCT ID: NCT02276872 Org: User:
Start: 12/18/14 End: 07/20/17 Due: 07/20/18

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT01795950 Org: User:
Start: 04/30/13 End: 01/31/16 Due: 01/31/17